Navigation Links
Major breakthrough toward the treatment of HIV/HAART-associated Lipodystrophy Syndrome
Date:12/5/2007

Montreal, December 5, 2007 Researchers in Montreal and Boston have identified a potential new treatment for the HIV/HAART*-associated Lipodystrophy Syndrome. This syndrome is a common side-effect of anti-retroviral medications to treat HIV infection. Dr. Julian Falutz, Director of the HIV Metabolic Clinic at the McGill University Health Centre (MUHC), and Dr. Steven Grinspoon, Director at the Massachusetts General Hospital Program in Nutritional Metabolism are publishing the results of their recent clinical trial in the December 6, 2007 issue of the New England Journal of Medicine.

The Lipodystrophy Syndrome consists of several metabolic disruptions that lead to abnormal lipid and glucose levels, as well as a generalized decrease in superficial fat tissues and an increase in deep abdominal fat. The observed body shape changes may cause significant impairment of patients quality-of-life leading many patients to stop taking their anti-retroviral medications. But the major health-threat related to the development of the Lipodystrophy Syndrome is an increased long-term cardiovascular risk.

Early in this decade, Dr. Falutz and Dr. Grinspoon began collaborating with Theratechnologies Inc., a Montreal-based biotechnology company that had developed a synthetic analogue of the naturally occurring growth hormone-releasing factor (GRF-tesamorelin). Its action is to regulate growth hormone levels that are important in controlling various metabolic processes. The effectiveness of this drug in reducing increased deep abdominal fat, and secondarily decreasing blood lipid levels, was initially confirmed in a small phase II study published in 2005. The current published results are from a large phase III Study conducted at 43 centers in the USA and Canada, which followed 412 patients for 6 months.

Its conclusions are decisive: Patients treated with tesamorelin saw their abdominal fat decrease by 15% on average, compared to a 5% average increase f
'/>"/>

Contact: Isabelle Kling
isabelle.kling@muhc.mcgill.ca
514-934-1934
McGill University
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
2. Laboratory at UI plays major role in diagnosing cancer
3. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
4. DaVita Acquires Majority Stake in HomeChoice Partners, Inc.
5. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
6. Major grant advances UWs clinical and translational research enterprise
7. Major differences revealed in how local authorities in the UK support disabled people
8. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
9. Worldwide Probiotic Drink, Yakult(R), Launches in Its First Major U.S. Market
10. Ericom Provides Significant Cost-Savings for Major New York City Healthcare Organization
11. Eckert Seamans Announces Major Expansion in Philadelphia, West Chester and Harrisburg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...oger Williams has called for a ban on an artificia...tion of 6,000 types of medicines, food and drinks....he sweetener, which is used in cereal, chocolate a... Foundation has published reports that aspartame c...
...i Ramachandra Medical College and Research Institu... LifeCell have announced a joint venture towards e...lity in the city.// The umbilical cord blood stem ...ard to treating a variety of diseases. The focus o...
...licted with the Alzheimer's disease is expected to...y and the population explosion in developing natio...mentia which is connected to cardiovascular diseas...igure is expected to rise to 42 million, and to 81...
...e Mellon University have reported in the Journal P...s and being happy protects from chronic illness an...ch study was led by Professor Sheldon Cohen team w...lth as they feel that it enhances the immune syste...
Other Medicine News:
(Date:10/6/2008)...ial Showed REMICADE Therapy is More Likely to Indu...mpared with Standard Immunomod...wswire/ -- Data presented for the first time,from ...e Naive to,Immunomodulators and Biologic Therapy (...to care of patients with moderate to severe Crohn,...
(Date:10/6/2008)...netic Characteristics of Naltrexone SR Associated ...l Trials -, PHOENIX, Oct. 6 /PRNewswire-FirstCall... a biopharmaceutical company focused on the treatm...lated disorders, today presented,data showing the ...,bupropion SR), successfully achieved key objectiv...
(Date:10/5/2008)... in New England Journal of Medicine reaffirm,well-...of SPIRIVA(R),HandiHaler(R), RIDGEFIELD, Conn., a...,UPLIFT (Understanding Potential Long-term Impacts...PIRIVA(R) HandiHaler(R) (tiotropium bromide,inhala...ion for up to 4,years as measured by FEV(1) (p<0.0...
(Date:10/2/2008)...rgent PC clinical success and expanded reimburseme...APOLIS, Oct. 2 /- Uroplasty...of the first patients in a new,randomized, control...Urgent,PC neuromodulation system for the treatment...rgency, urge incontinence and frequency of urinary...
Breaking Medicine Technology:New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 2Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 3Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 4Karmanos Researchers Study the Impact of Galectin 3 on Breast Cancer Disparity in Caucasian and Asian Women 1768 1Karmanos Researchers Study the Impact of Galectin 3 on Breast Cancer Disparity in Caucasian and Asian Women 1768 2Karmanos Researchers Study the Impact of Galectin 3 on Breast Cancer Disparity in Caucasian and Asian Women 1768 3Stem Cell Marker Controls Pair of Key Cancer Pathways 16714 1Stem Cell Marker Controls Pair of Key Cancer Pathways 16714 2Celebrex Lipitor combo may halt prostate cancer 16711 1Celebrex Lipitor combo may halt prostate cancer 16711 2Celebrex Lipitor combo may halt prostate cancer 16711 3Decrease in mortality after severe injuries in accidents 16708 1
..., 2007 /PRNewswire/ -- D-Pharm announced,today tha...protective compound DP-b99 in the treatment of acu...he European Stroke,Conference. The data will be pr...or Prof. H. C. Diener, on Thursday May 31st at,14....Conference,Center in Glasgow. The abstract for the...
...RNewswire-USNewswire/ -- Evidence is,accumulating ...,reports the June 2007 issue of Harvard Women,s He...50 and over who regularly took,antidepressants cal...) had double the rate of fractures as people not u...pression itself as a source,of endocrine changes t...
Other Medicine Technology:DP-b99 Phase IIb Trial Results to be Presented at the European,Stroke Conference 2DP-b99 Phase IIb Trial Results to be Presented at the European,Stroke Conference 3Antidepressant Use May Boost Fracture Risk, From Harvard Women's,Health Watch 2
Standard locking pliers.
The double action wire cutter has both side and end cutting capabilities.
...he companys core product. It is created using the ... for the screening of eye and non-eye diseases and...xamination basis and is non-reimbursable. The opto...field of view of the patients retina which is view...
...angular Camera ,IS2s Single Rectangular Head...nd SPECT studies. Offering flexibility, ease of us...r Head Camera is an ideal camera for bone and orga...d also acquires excellent cardiac images. Its also...
Medicine Products: